ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing more...
NOHO, INC. PROVIDES OPERATIONS UPDATE AND FORECAST FOR 2022
Scottsdale, Arizona, Dec. 02, 2021 (GLOBE NEWSWIRE) — NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the “Company”), announced the following: Our Company has seen an amazing resurgence in 2021. In a mere eight months, we more...
Identiv Appoints Justin Scarpulla as Chief Financial Officer
Identiv Appoints Justin Scarpulla as Chief Financial Officer Strategic SpaceX and Semiconductor Industry Financial Leader Joins to Lead Company Growth PR Newswire FREMONT, Calif. , Dec. 2, 2021 /PRNewswire/ — Identiv, Inc. (NASDAQ: INVE), a more...
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first more...
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow
BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present more...
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement Combined company will operate as EOM Pharmaceuticals Holdings, Inc. advancing a pipeline of novel immunomodulatory agents including EOM613 currently more...
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021
Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit Oncocyte will support a Continuing Medical Education event on Immunotherapy Biomarkers at more...
SIBANNAC, INC. PROVIDES FINANCIAL AND OPERATIONS UPDATE
Scottsdale, Arizona, Dec. 02, 2021 (GLOBE NEWSWIRE) — Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the “Company”), announced the following: Sibannac has made great strides in 2021. With the addition of Eric Stoll and Lifetime more...
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1’22 LAVAL, Québec, Dec. 02, 2021 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or more...
CTG and Micro Focus Extend European Platinum Partnership to French Market
PARIS, Dec. 02, 2021 (GLOBE NEWSWIRE) — CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced an expanded strategic partnership agreement with Micro Focus more...